The company will highlight subgroup analyses in abdominal and cardiac MRI, MRA applications, CNS imaging findings, and workflow-focused radiology technologies.
Focus on Low-Dose MRI Contrast Agent Development
Bayer will showcase updates from its radiology portfolio at the European Congress of Radiology (ECR) 2026, taking place March 4-8 in Vienna, Austria. According to the company, the presentations will center on contrast agent research, injector technologies, and data-driven connectivity solutions designed to support efficiency and clinical decision-making in radiology workflows.
A major scientific focus will be gadoquatrane, Bayer’s investigational low-dose macrocyclic gadolinium-based contrast agent (GBCA) for contrast-enhanced magnetic resonance imaging (MRI). Bayer plans to share new subgroup data from its pivotal Phase III clinical development program across several clinical settings.
Phase III Data Across Multiple MRI Applications
At ECR 2026, Bayer will present results on the efficacy and safety of gadoquatrane in:
- Abdominal MRI
- Cardiac MRI
- Magnetic resonance angiography (MRA)
- Central nervous system (CNS) imaging
- Pharmacokinetics modeling and regulatory-focused analyses
Across the clinical development program, gadoquatrane was investigated at a gadolinium dose of 0.04 mmol Gd/kg body weight, representing a 60% reduction compared with standard macrocyclic GBCAs dosed at 0.1 mmol Gd/kg.
Bayer noted that these scientific sessions build on positive topline results from the QUANTI Phase III program announced in 2025. The company has submitted marketing authorization applications for gadoquatrane in Japan, the U.S., the EU, China, and additional markets.
Executive Perspectives from Bayer and ECR Leadership
“We are delighted to join this year’s European Congress of Radiology, a premier global forum for us to engage with the community as a place where scientific exchange, education, collaboration and innovation converge to improve patient care,” said Nelson Ambrogio, President Radiology, Bayer. “As a committed partner to the radiology community and a leader in the field, Bayer is proud to showcase cutting-edge science, present expert-led symposia and advance technologies that help clinicians in their daily work. We look forward to continuing our support of the radiology community, striving to translate knowledge into better outcomes for patients worldwide.”
ECR 2026 Congress President Minerva Becker emphasized the role of collaboration in imaging research: “ECR 2026 is driven by the belief that scientific progress in radiology depends on open exchange and strong collaboration,” stated Minerva Becker, ECR 2026 Congress President. “The congress brings together leading experts and innovative industry partners to advance research and translate innovation into clinical practice. Contributions such as Bayer’s, grounded in robust clinical science and technological development, highlight the value of partnership in shaping the future of radiology for patient benefit.”
Scientific Sessions Scheduled at ECR 2026
Bayer will contribute multiple gadoquatrane-focused presentations, including sessions in neuroimaging, vascular imaging, abdominal MRI, and cardiac clinical trials, as well as posters covering MR angiography and pharmacokinetics.
Source: Bayer
